Nuvation Bio Inc. (NUVB)
NYSE: NUVB · IEX Real-Time Price · USD
2.680
+0.060 (2.29%)
At close: Apr 26, 2024, 4:00 PM
2.740
+0.060 (2.24%)
After-hours: Apr 26, 2024, 7:53 PM EDT
Nuvation Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 6.33, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 136.19% from the current stock price of 2.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +86.57% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $8 | Strong Buy | Maintains | $5 → $8 | +198.51% | Mar 28, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $1.4 → $10 | Hold → Strong Buy | Upgrades | $1.4 → $10 | +273.13% | Mar 27, 2024 |
| BTIG | BTIG | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +86.57% | Mar 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +86.57% | Mar 7, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.38
from -0.35
EPS Next Year
-0.55
from -0.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 29.7M | 127.0M | 347.3M |
| Avg | n/a | n/a | 20.0M | 78.6M | 168.7M |
| Low | n/a | n/a | 10.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 536.2% | 341.6% |
| Avg | - | - | - | 294.2% | 114.5% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.32 | -0.46 | -0.51 | -0.34 | -0.46 |
| Avg | -0.38 | -0.55 | -0.70 | -0.39 | -0.45 |
| Low | -0.44 | -0.61 | -0.86 | -0.44 | -0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.